FDA.reportPublic FDA data

Bosulif

RxCUI
1307625
RxNorm name
Bosulif
Term type
BN
Status
Active
Updated
2026-07-22 07:08:48

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
102012
Active start
102012
Multiple ingredient
NO
Branded
YES

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
bosutinib1307619

Source Vocabulary Codes#

Code type, Value, Category table
Code typeValueCategory
PRESCRIBABLEYATTRIBUTES
RXNAV_STRBosulifNAMES
RxNorm NameBosulifNAMES
TTYBNATTRIBUTES
RxCUI1307625CODES
MMSL_CODEBN192772CODES

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCL01EABCR-ABL tyrosine kinase inhibitorsATC1-4bosutinib
FDASPLN0000175605Kinase InhibitorEPChas_epcbosutinib
FDASPLN0000020009Bcr-Abl Tyrosine Kinase InhibitorsMOAhas_moabosutinib
MEDRTD000814Aniline CompoundsCHEMhas_ingredientbosutinib
MEDRTD009570NitrilesCHEMhas_ingredientbosutinib
MEDRTD011804QuinolinesCHEMhas_ingredientbosutinib
MEDRTD004342Drug HypersensitivityDISEASEci_withbosutinib
MEDRTD004342Drug HypersensitivityDISEASEci_withbosutinib monohydrate
MEDRTD015464Leukemia, Myelogenous, Chronic, BCR-ABL PositiveDISEASEmay_treatbosutinib
MEDRTD015464Leukemia, Myelogenous, Chronic, BCR-ABL PositiveDISEASEmay_treatbosutinib monohydrate
MEDRTN0000020001Tyrosine Kinase InhibitorsMOAhas_moabosutinib
MEDRTN0000020001Tyrosine Kinase InhibitorsMOAhas_moabosutinib monohydrate
MEDRTN0000175672Cellular Proliferation AlterationPEhas_pebosutinib
MEDRTN0000175672Cellular Proliferation AlterationPEhas_pebosutinib monohydrate

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESBN_CARDINALITYsingle
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESPRESCRIBABLEY
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESTTYBN
CODESMMSL_CODEBN192772
CODESRxCUI1307625
NAMESRXNAV_STRBosulif
NAMESRxNorm NameBosulif
SOURCESSourceMultum MediSource Lexicon